What a yes vote endorsed
Stem Cell Therapeutic and Research Reauthorization Act of 2025
What this does
The bill reauthorizes the Stem Cell Therapeutic and Research Act of 2005, extending the federal stem cell and cord blood transplantation programs through fiscal year 2031. It authorizes $33,009,000 for each of fiscal years 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program, the national bone marrow and cord blood matching program. It replaces the National Cord Blood Inventory's fixed target of at least 150,000 new units with "a sufficient supply, as determined by the Secretary," of high-quality cord blood units. It directs the Secretary to manage the inventory's size and composition to maximize clinical utility and genetic diversity, and it lets the Secretary transfer units from a cord blood bank that is no longer operational to another qualified bank.
Passed the House by voice vote
How we know · 6 sourced claims
- The bill reauthorizes the Stem Cell Therapeutic and Research Act of 2005 through fiscal year 2031.Source: Sec. 2 and Sec. 3(f)
- It authorizes $33,009,000 for each of fiscal years 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program.Source: Sec. 2
- The C.W. Bill Young Cell Transplantation Program is the national bone marrow and cord blood matching program.Source: Sec. 2 (heading)
- It replaces the National Cord Blood Inventory's fixed target of at least 150,000 new units with a sufficient supply, as determined by the Secretary, of high-quality cord blood units.Source: Sec. 3(a)
- It directs the Secretary to manage the inventory's size and composition to maximize clinical utility, ensure genetic diversity, and promote efficient use of resources.Source: Sec. 3(d)
- It lets the Secretary transfer units from a cord blood bank that is no longer operational to another qualified bank.Source: Sec. 3(b)
Reported lobbying
At least
8
organizations named this measure in a lobbying filing.
A floor, not a total. Those organizations were counted by the client name on 18 quarterly reports filed by 8 registered lobbying firms in 2025 Q3, 2025 Q4, 2026 Q1 and 2026 Q2. The disclosure form takes a free text description of the issue, so an organization that lobbied this measure without naming it is not counted here.
The filings record that lobbying was reported on the measure. They carry no per-bill dollar figure and no position, so nothing here says how much was spent or which side an organization took.
5 of them, in no ranking
- NMDP
- ASTCT
- NATIONAL MARROW DONOR PROGRAM
- AMERICAN ASSOCIATION OF BLOOD BANKS, DBA ASSOCIATION FOR THE ADVANCEMENT OF BLOO
- AMERICAN BENEFITS COUNCIL
Listed as filed, in the order the filings were read, and 3 others are not shown. These are not the largest, the earliest or the most active: the extract keeps five names per measure and no ranking is available.
From the LD-2 quarterly lobbying filings published at lda.gov by the Senate Office of Public Records. Read for 2025 Q1, 2025 Q2, 2025 Q3, 2025 Q4, 2026 Q1 and 2026 Q2. The pull came up 2 short in 2025 Q4 and 7 short in 2026 Q2 against the register's own count, so those quarters are the filings posted rather than every one filed. 2026 Q3 is still inside its filing window, so that quarter is only the filings posted so far.